Project Grant HT94252510355
Award Date
6/15/25
Completion Date
6/14/28
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
The Ohio State University will receive $1,181,604 under a four-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The funding will support research into developing new methods to access extracellular vesicle MDM2 DNA cargo as a potential biomarker for liposarcoma. The grant aims to transform health care for service members and the public through innovative biomedical research investigating medical solutions for...
This $630,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports The Ohio State University's research to develop a targeted antibody and immunotoxin combination therapy to improve treatment of T-cell lymphoma. The award period is from July 15, 2023 to July 14, 2025. This research aims to transform health care for Service Members and the American public through innovative and impactful medical solutions for the...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to The Ohio State University to support research on PPP2R1B IN DEDIFFERENTIATED LIPOSARCOMA. The project will be performed in Columbus, OH and run from Sep 30, 2023 through Sep 29, 2026. The Ohio State University has a history of conducting biomedical research and providing clinical trial coordination services to federal agencies like the National...
The federal Project Grant award for $1,317,976.00, awarded by the Defense Health Agency and funded under the Military Medical Research and Development program (CFDA 12.420), is supporting research at The Ohio State University to target the RAL G proteins in order to treat triple-negative breast cancer. The project aims to develop innovative approaches for preventing and managing this aggressive form of breast cancer, which disproportionately affects military personnel and veterans. The 3-year...
This federal Project Grant award with ID HT94252510334, valued at $826,875.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) grant program. The grant supports research at The Ohio State University to investigate "Novel Roles of SLIT2 in Enhancing Antitumor Immunity in Small Cell Lung Cancer". The research project aims to explore innovative approaches to cancer treatment, with a focus on leveraging the SLIT2 protein to...
The Department of the Army Medical Command awarded a $3,874,682 Project Grant to The Ohio State University Office of Sponsored Programs under the Military Medical Research and Development program. The grant will fund research from July 1, 2022 to June 30, 2026 to investigate the mechanisms of metastasis suppression and develop translational applications in thyroid cancer. As part of the Military Medical Research and Development program's goal to transform military and public health through...
The Ohio State University received a $156,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award beginning in June 2021 will support research on Fatty Acid Binding Protein-5 as a novel therapeutic target against aggressive lung cancer. Through this funding, The Ohio State University researchers will investigate medical solutions for lung cancer, advancing the Military Medical Research...
This $472,498 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at The Ohio State University to target the UPP1-mediated pyrimidine salvage pathway to prevent ovarian cancer recurrence. The research aims to develop innovative approaches to disease prevention, diagnosis, and treatment for conditions relevant to military personnel and the broader public. This 2-year project,...
The Department of the Army Medical Command awarded a $472,500 Project Grant (CFDA 12.420 - Military Medical Research and Development) to The Ohio State University to explore the role of CHD1L expression as an early event in high-grade serous ovarian cancer. This 2-year research project, with a performance period from June 1, 2024 to May 31, 2026, aims to advance the understanding of this form of ovarian cancer to support the development of improved diagnostic tools and treatments for military...
This federal Project Grant award of $1,251,451 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) aims to support research on metastatic progression in medullary thyroid cancer. The award period runs from July 1, 2023 to June 30, 2027 and will be carried out by the prime awardee, The Ohio State University (OSU). Under the grant, OSU will conduct genomic sequencing studies and organoid/metastasis-on-a-chip studies to investigate...